Replidyne's Phase III clinical program for the treatment of community-acquired respiratory tract infections in adults and children

Sept. 17, 2007 - Replidyne, Inc. (Nasdaq: RDYN) announced that it will be presenting 21 posters highlighting three major pipeline programs at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held at the McCormick Place conference center in Chicago. The posters will showcase previously unpublished data related to faropenem medoxomil (faropenem), Replidyne's Phase III clinical program for the treatment of community-acquired respiratory tract infections in adults and children.. Replidyne's Press release.